





Human campylobacteriosis in the European Union

Dr Andrea Ammon, Acting Director
ECDC, European Centre for Disease Prevention and Control
EP ENVI committee meeting, 15 September 2015
Exchange of views with the European Commission, EFSA and ECDC

Campylobacter infection in humans – clinical picture and outcomes




Trend in human campylobacteriosis cases in the EU/EEA, 2008-2014*




- *Campylobacter* human infections: over 200 000 cases reported annually
- In 2013, about 43% of cases hospitalized (N=27 357)
- In 2013, 56 deaths recorded
- Statistically increasing trend in 2008-2014 (10% increase in 2014)

Trend of campylobacteriosis cases by age group in the EU/EEA, 2008-2014, preliminary data*




Campylobacteriosis burden assessment



Antimicrobial resistance in *Campylobacter* isolates

Resistance to ciprofloxacin



Low multi-drug resistance and co-resistance to critically important antimicrobials

Summary of campylobacteriosis in EU

- Increasing trend
- Over 200 000 cases reported annually
- Estimated 2,4 million cases annually
- Estimated over 420 million infections annually
- High resistance levels to fluoroquinolones (ciprofloxacin)
- Low multidrug and co-resistance to critically important antimicrobials
- ECDC activities:
 - Study on association with use of antacids
 - Close collaboration with EFSA => joint reports
- Successful control needs a holistic approach: One Health!